The initial results are expected by the second week of May, 2008. These animal studies will be conducted by Krishna Menon, a world-renowned authority in preclinical and toxicological studies of novel therapeutics.
Anil Diwan, president of NanoViricides, said: “This is a proof of principle study and will be expanded further with a larger follow-up study to be performed at a major government research institution later in the year.”